Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Jilin Province Huinan Changlong Bio-pharmacy Co's retained earnings for the quarter that ended in Jun. 2026 was HK$1,933 Mil.
Jilin Province Huinan Changlong Bio-pharmacy Co's quarterly retained earnings
declined
from Jun. 2025 (HK$1,740 Mil) to Dec. 2025 (HK$1,710 Mil) but then
increased
from Dec. 2025 (HK$1,710 Mil) to Jun. 2026 (HK$1,933 Mil).
Jilin Province Huinan Changlong Bio-pharmacy Co's annual retained earnings
increased
from Dec. 2023 (HK$1,466 Mil) to Dec. 2024 (HK$1,590 Mil) and
increased
from Dec. 2024 (HK$1,590 Mil) to Dec. 2025 (HK$1,710 Mil).
Jilin Province Huinan Changlong Bio-pharmacy Co (HKSE:08049) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Jilin Province Huinan Changlong Bio-pharmacy Co Retained Earnings Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jilin Province Huinan Changlong Bio-pharmacy Co Retained Earnings Chart
Jilin Province Huinan Changlong Bio-pharmacy Co Annual Data
Jilin Province Huinan Changlong Bio-pharmacy Co Retained Earnings Calculation
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
What does a Retained Earnings of HK$1,933 Mil mean?
Jilin Province Huinan Changlong Bio-pharmacy Co (HKSE:08049) has a Retained Earnings of HK$1,933 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Jilin Province Huinan Changlong Bio-pharmacy Co and its competitors.
Is Jilin Province Huinan Changlong Bio-pharmacy Co's Retained Earnings too high?
Jilin Province Huinan Changlong Bio-pharmacy Co's current Retained Earnings is HK$1,933 Mil. Overall, Jilin Province Huinan Changlong Bio-pharmacy Co has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jilin Province Huinan Changlong Bio-pharmacy Co's Retained Earnings compare to ZTS?
Jilin Province Huinan Changlong Bio-pharmacy Co's Retained Earnings of HK$1,933 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Jilin Province Huinan Changlong Bio-pharmacy Co and its competitors. Jilin Province Huinan Changlong Bio-pharmacy Co's current Retained Earnings is HK$1,933 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jilin Province Huinan Changlong Bio-pharmacy Co stock overvalued right now?
Based on GuruFocus' analysis, Jilin Province Huinan Changlong Bio-pharmacy Co (HKSE:08049) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$1.82, compared to a current price of HK$2.33 — trading 27.7% above its estimated fair value. The current Retained Earnings is HK$1,933 Mil. Jilin Province Huinan Changlong Bio-pharmacy Co's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Jilin Province Huinan Changlong Bio-pharmacy Co (HKSE:08049), the current Retained Earnings is HK$1,933 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jilin Province Huinan Changlong Bio-pharmacy Co (HKSE:08049) Overvalued in 2026?
Based on GuruFocus' analysis, Jilin Province Huinan Changlong Bio-pharmacy Co stock appears to be overvalued.
The current stock price of HK$2.33 is trading 27.7% above its estimated GF Value™ of HK$1.82.
GuruFocus considers Jilin Province Huinan Changlong Bio-pharmacy Co to be Modestly Overvalued.
Key valuation signals for HKSE:08049:
Retained Earnings: HK$1,933 Mil
GF Value™: HK$1.82 vs. price of HK$2.33 (27.7% above fair value)
No single metric tells the full story. See the HKSE:08049 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is principally engaged in the manufacture and distribution of Chinese medicines and pharmaceutical products in the PRC under the brand names of Changlong and Qing Tong. The company has only one business segment. It generates revenue from the Sales of Chinese medicines and pharmaceutical products. Geographically, it derives its entire revenue from the PRC.
74GF Score
Get the complete analysis for HKSE:08049
Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08049 has been successfully added to your 
